The OCMX™ is pleased to announce the listing of Vitanova Biomedical to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

SAN ANTONIO, TX, September 10, 2020 /24-7PressRelease/ — Vitanova Biomedical (VNB) is a San Antonio, TX-based preclinical stage biotech company developing a University of Texas invented novel light-activated targeted cancer therapy platform technology, Light Activated Intracellular Acidosis (LAIA) therapy.

LAIA therapy has proven capable of killing _80% of cancer cells in _ 2 minutes after light exposure in five different cancer types including pancreatic, breast, and prostate cancer in vitro, and reducing cancer volume and extending life in vivo utilizing triple negative breast cancer.

The OCMX™ is pleased to announce the listing of Vitanova Biomedical to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

The OCMX™ has spent considerable time completing its due diligence on Vitanova Biomedical and concluded that there is indeed a tremendous opportunity for Investors and Advisors.

The OCMX™ noted that Vitanova Biomedical exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.


1. LAIA therapy is minimally invasive, effective, and targeted to specific cancer types. Due to this targeting, LAIA therapy will minimize damage to near-by health tissue, and potentially eliminate unwanted debilitating side effects currently associated with surgery, radiation therapy, chemotherapy, and/or active surveillance.

2. VNB is pursuing prostate cancer as their lead indication and has the ability to pursue multiple additional cancer indications including breast, ovarian, glioblastoma, pancreatic, etc. by changing the specific cancer targeting agent on their core drug compound. LAIA therapy is proven capable of killing five different cancer cell types including pancreatic, triple negative breast, and prostate cancer.

3. LAIA therapy has a lowered product development risk profile as it is based upon three accepted principles of cancer therapy: 1) Intracellular acidosis causes pH-induced cancer cell death; 2) Compounds, such as porphyrins, can be activated by specific wavelengths of light to elicit a biological response; and 3) Nanoparticles have been selectively targeted to cancer using antibody-antigen or ligand-receptor conjugates.

4. LAIA therapy has a lowered regulatory risk profile and clear pathway as two of the three LAIA combination therapy components have already been approved by the FDA. VNB has entered a global strategic corporate partnership with LiteCure Medical Lasers combining VNB’s light-activated targeted cancer drug with LiteCure’s advanced FDA-approved laser light and probe technology.


Tom Roberts, CEO and Chairman
Mr. Roberts has over 30 years of successful senior leadership experience in large, mid-cap, and start-up healthcare technology companies. During this time, Tom has led the progression of more than 10 innovative healthcare technologies from ideation, through product development and regulatory approval, to market commercialization.

Matthew Gdovin, Ph.D., Founder and CSO
Upon receiving his Doctorate in Physiology from Dartmouth College, Dr. Gdovin focused most of his 21 years in academia studying pH regulation. Dr. Gdovin is the inventor of, and recognized expert in the ability to disrupt intracellular pH regulation in cancer to cause cancer cell death through Light-Activated Intracellular Acidosis.

Greg Espenhover, CPA, Co-founder and CFO
Mr. Espenhover is a member of the American Institute of Certified Accountants and Texas State Board of Accountancy. Additionally, Greg is a Partner and Shareholder of Davidson Freedle Espenhover and Overby, P.C., and has over 30 years of experience providing accounting, tax, and business consulting services to a diverse set of businesses.

Harald Stock, Ph.D., Incoming Non-Executive Director
Dr. Stock is a serial CEO, entrepreneur, investor, and Board Director with over 20 years of experience in healthcare, including 10 years of experience in big pharma (Roche, J&J). In addition to his role with Vitanova Biomedical, Harald is the Co-founder of CognifiSense, a Silicon Valley-based digital neuroscience therapy company, and Executive Chairman of Blue Therapeutics.


The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

For the original version of this press release, please visit here